BioNTech SE

NASDAQ:BNTX

Biotechnology

Healthcare
$83.26 -1.52%

-$1.41 today

Market cap
$20.64B
Beta
1.32
P/E (TTM)
-16.2
EPS (TTM)
-$4.93
52W Low $79.52High $124.00

Volume 1.24M

Average 1.11M

BNTX Depreciation & Amortization

Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.

BioNTech SENASDAQ: BNTX

Depreciation & Amortization · Q2 FY2026 · quarter ended Jun 2026

Depreciation & amortization growth accelerates

Q2 FY2026 depreciation & amortization of €266.1M rose 421.8% year over year, ahead of the +122.9% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 115.8% from the prior quarter. Over 3 fiscal years it compounded at +43.9% a year.

Context

  • Depreciation & amortization amounted to 13.3% of revenue in FY2025, up 2.5 pp from a year earlier.
  • Depreciation & amortization increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +421.8% holds above the trailing-twelve-month pace of +122.9%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
€266.1M+115.8% QoQ
Last fiscal yearDec 2025
€367.69M+23.4% YoY
LTMJun 2026
€676.85M+122.9% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+421.8%——
1 year+23.4%——
3-year CAGR+43.9%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

EUR · from the income statement

Latest · FY2025
367.69M EUR
Year-over-year change
+23.4%
4-year CAGR
+48.7%

Depreciation & Amortization vs competitors

How BNTX compares with its peers on the latest reported figures

  • Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +122.9% is the highest of 9, against a peer median of -3.8%.
  • Depreciation & amortization amounts to 25.6% of revenue for BNTX, versus a peer median of 3.1%.
BNTX Competitors
Depreciation & Amortization for BNTX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BNTXBioNTech SELTM Jun 2026€676.85M EUR+122.9%+43.9%25.6%
INCYIncyte CorporationLTM Jun 2026$98.28M USD+8.6%+11.2%1.7%
GMABGenmab A/SLTM Jun 2026$44M USD—-41.9%1.1%
IOVAIovance Biotherapeutics, Inc.LTM Sep 2026$42.96M USD-7.4%+30.8%11.3%
IBRXImmunityBio, Inc.LTM Sep 2026$16.54M USD+4.6%-5.3%9.1%
IMTXImmatics N.V.LTM Mar 2026€12.04M EUR-2.6%+21.9%32.3%
XNCRXencor, Inc.LTM Jun 2026$10.17M USD-10.7%+6.1%9.7%
MGNXMacroGenics, Inc.LTM Mar 2026$7.09M USD-5.1%-15.4%4.5%
IMCRImmunocore Holdings plcLTM Mar 2026$3.14M USD-22.4%-18.0%0.8%
TGTXTG Therapeutics, Inc.LTM Sep 2026$316K USD+32.2%-22.0%0.0%
CGENCompugen Ltd.LTM Mar 2026$0 USD—-0.5%0.0%
Peer median (excluding BNTX) —-3.8%-2.9%3.1%

Competitors are the stored peer set for BNTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue18.98B17.31B3.82B2.75B2.76B
Cost of Revenue2.91B3B599.8M541.3M616.47M
Gross Profit16.07B14.32B3.22B2.21B2.14B
Gross Margin84.7%82.7%84.3%80.3%77.6%
Research & Development949.2M1.54B1.78B2.25B2.02B
Selling, General & Admin327.2M541.2M557.7M599M698.2M
Operating Expenses781.4M1.67B2.53B3.52B2.76B
Depreciation & Amortization75.2M123.3M183.4M298M367.69M
EBITDA15B13.1B1.38B(367.1M)(628M)
EBITDA Margin79.1%75.7%36.1%-13.3%-22.8%
Operating Income15.28B12.64B690.4M(1.31B)(623.87M)
Operating Margin80.5%73.0%18.1%-47.8%-22.6%
Interest Income1.56M47.37M351.31M0252.24M
Interest Expense5.63M15.82M7.76M13.16M13.64M
Other Income / Expenses(237.4M)311.4M495.7M636.6M(385.46M)
Income Before Tax15.05B12.95B1.19B(677.7M)(1.01B)
Pre-Tax Margin79.3%74.8%31.1%-24.6%-36.6%
Income Tax Expense4.75B3.52B255.8M(12.4M)81.93M
Net Income10.29B9.43B930.3M(665.3M)(1.09B)
Net Margin54.2%54.5%24.4%-24.2%-39.6%
EPS (Basic)43.8738.083.87(2.77)(4.51)
EPS (Diluted)41.2137.093.83(2.77)(4.51)
Weighted Avg Shares244M243.3M240.6M240.4M241.7M
Weighted Avg Shares (Diluted)259.7M249.8M242.7M240.4M241.7M

BioNTech SE

NASDAQ:BNTX

Intrinsic Alpha fair value

Locked

Current Price

$83.26

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.